DDInter1640 DDInter1694
Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared to other antiretroviral therapies. While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%), its current indications require the co-administration of ritonavir - a potent enzyme inhibitor - that increases the bioavailability and subsequent serum concentrations of saquinavir, thus dramatically improving antiviral activity.[A214382,L3450,L14351]
Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. It is administered orally and is odorless, tasteless, and stable at room temperature. Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and the median time to achieving normal potassium levels in the blood was 2.2 hours, with 92% of patients achieving normal potassium levels within 48 hours following administration. The treatment effect was maintained for up to 12 months.
Saquinavir {u} (Compound) resembles {v} (Compound) Lopinavir
Saquinavir {u} (Compound) resembles {v} (Compound) Nelfinavir
Saquinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Saquinavir {u} (Compound) binds {v} (Gene) SLCO1B1
Saquinavir {u} (Compound) upregulates {v} (Gene) UBQLN2
Saquinavir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Saquinavir {u} (Compound) downregulates {v} (Gene) COG2
Saquinavir {u} (Compound) causes {v} (Side Effect) Renal failure acute
Saquinavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Saquinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin human
Saquinavir (Compound) resembles Lopinavir (Compound)
Saquinavir (Compound) resembles Nelfinavir (Compound)
Saquinavir (Compound) treats acquired immunodeficiency syndrome (Disease)
Saquinavir (Compound) binds SLCO1B1 (Gene)
Saquinavir (Compound) upregulates UBQLN2 (Gene)
Saquinavir (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class)
Saquinavir (Compound) downregulates COG2 (Gene)
Saquinavir (Compound) causes Renal failure acute (Side Effect)
Saquinavir may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin human